Bicycle Therapeutics Plc ADR [BCYC] stock prices are up 13.90% to $15.16 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCYC shares have gain 1.81% over the last week, with a monthly amount drifted -27.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Equal-Weight rating and assigned the stock a price target of $25. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on September 06, 2024, and set its price target to $35. On August 07, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $28 on the stock. B. Riley Securities upgraded its rating to a Buy. Cowen initiated its recommendation with a Outperform. Barclays started tracking with a Overweight rating for this stock on July 28, 2022, and assigned it a price target of $30.
The stock price of Bicycle Therapeutics Plc ADR [BCYC] has been fluctuating between $12.17 and $28.67 over the past year. Currently, Wall Street analysts expect the stock to reach $39.25 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $15.16 at the most recent close of the market. An investor can expect a potential return of 158.91% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
The Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] reported sales of 36.97M for trailing twelve months, representing a drop of -49.19%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -5.95%, Pretax Profit Margin comes in at -5.21%, and Net Profit Margin reading is -4.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.27 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.02 points at the first support level, and at 12.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.73, and for the 2nd resistance point, it is at 16.31.
Ratios To Look Out For
It’s worth pointing out that Bicycle Therapeutics Plc ADR [NASDAQ:BCYC]’s Current Ratio is 17.13. Further, the Quick Ratio stands at 17.13, while the Cash Ratio is 15.79. Considering the valuation of this stock, the price to sales ratio is 28.30, the price to book ratio is 1.26.
Transactions by insiders
Recent insider trading involved Thompson Travis Alvin, CHIEF ACCOUNTING OFFICER, that happened on Jan 06 ’25 when 2686.0 shares were sold. CHIEF ACCOUNTING OFFICER, Thompson Travis Alvin completed a deal on Jan 02 ’25 to sell 1750.0 shares. Meanwhile, CHIEF ACCOUNTING OFFICER Thompson Travis Alvin sold 159.0 shares on Jan 03 ’25.
